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The essence of this presentation is that under effective immuno-
suppression, there is a migration of sessile (passenger) leukocytes 
(prominently but not limited to dendritic cells) from the graft into 
ubiquitous recipient tissues, and replacement of these cells in the 
graft by similar leukocytes from the recipient. The consequence is 
a body wide engagement of donor and recipient cells followed, we 
believe, with variable donor and recipient-specific nonreactivity 
that mayor may not require lifetime immunosuppression for 
stabilityl (Fig. 1). 
Neglected Early Clues 
The germ of this concept was stated ingenuously in the title of 
an article in 1963 which introduced the combined use of azathio-
prine and prednisone for renal transplantation- emphasizing, 
first, the ease with which kidney rejection could be reversed, and 
second, the collapse in time of antidonor immune reactivity.2 A 
characteristic clinical evolution in successful cases under azathio-
prine was a rejection, manifested by secondary functional failure of 
an initially well functioning allograft (fall in creatinine clearance 
and rise in BUN), reversal of these adverse events with augmented 
steroids, subsequent weaning of both steroids and azathioprine, and 
then a trouble-free survival lasting in the most successful cases for 
more than 30 years. 
The observations of rejection reversal and an altered donor-
recipient relation led in 1963 to development of an empiric 
therapeutic dogma upon which the specialty of whole organ 
transplantation is based. It calls for daily baseline treatment (origi-
nally azathioprine) plus trial and error intervention with the highly 
dose maneuverable adrenal conical steroids (or later antilymphoid 
agents) to whatever level is required to maintain stable graft 
function. Increasingly potent new drugs with different sites of 
action (listed in Table 1) have been added through the years, but the 
therapeutic dogma has never changed. 
Although this treatment policy was successful, there was no 
·Correspondence address: Thomas E. Srarzl, M.D., Ph.D., Department of 
Surgery, 3601 Fifth Avenue, 5C Falk Clinic, University of Pittsburgh, 
Pittsburgh, Pennsylvania, 15213. 
Aided by Projecr Grant No. DK 29961 from the Narional Institutes of Health, 
Bethesda, Maryland. • 
explanation why. A clue was found in tuberculin, coccidiodin and 
other delayed hypersensitivity skin tests on these pioneer kidney 
recipients and their donors. Seventy-seven percent of the skin 
reactions that were positive in the donors but not the recipients 
crossed over to the previously negative recipients, along with the 
transplanted kidneys. When this did not occur (the other 23%), it 
meant that the kidney transplant had failed. Our immunologists 
Kirkpatrick and Wilson, speculated that the migration of the skin 
tests was "caused by adoptive transfer of donor cellular immunity by 
leukocytes in the renal graft vasculature and hilar lymphoid tissue. "3 
Because the kidney was thought 30 years ago to be devoid of 
leukocytes, the credibility of the explanation was undermined. 
Proof of Chimerism 
After Kidney Transplantation 
That Kirkpatrick and Wilson had been right was proved nearly 
30 years later when five of the original Colorado patients who still 





Fig. 1. Current understanding of the graft and systemic c~limerism that occurs 
after intestinal transplantation. Note the automatic production of mixed 
allogenic chimerism, providing the preexisting immunologic apparatus is 
not iatrogenically damaged on either donor or recipient side (see text). 
Evolution of this concept permitted successful clinical intestinal transplan-
tation trials'" 
Table 1. Central Therapeutic Dogma 
Strategy Baseline Agents Sites of Action 
1. Baseline therapy 1. Azathioprine DNA synthesis 
with one or two drugs 
2. Cyclophosphamide DNA synthesis 
2. Secondary adjustments 
with steroids or 3. Cyclosporine 
antilyrnphoid agents 
3.Case to case trial 
and potential error) 
of weaning 
4. FK 50& 
IL-2 production 
IL-2 production 
bore their continuously functioning HLA mismatched kidneys, 
were restudied. In four of the cases, their volunteer donors were still 
alive and it was possible to show by mixed lymphocyte reaction 
(MLR) or cell mediated lymphocytotoxicity (CML) that there was 
donor-specific nonreactivity. Biopsies in the five patients were 
taken from the allograft and elsewhere. After immunostaining, 
viable donor cells that appeared to be dendritic cells were found in 
the lymph nodes and skin of all the recipients; the findings were 
confirmed with polymerase chain reaction (PCR).4 
The Liver and Other Extrarenal Organs 
Other early clues about cell migration came from the second vital 
organ to be transplanted - the liver. In 1969, it was shown that the 
liver graft quickly became a composite with replacement of its 
Kupffer cells and other interstitial leukocytes by recipient cells) -
a change assumed for nearly 20 years ro be a unique feature of the 
liver. However, in 1991, when it was seen by Murase6 and Iwak? 
that the transplanted intestine also was chimeric, it was realized that 
the changes must be generic with all organs. This soon was proved. 
Finally in 1992, at the same time as the kidney recipient studies 
already cited, but in far greater detail, it was proved with cytostaining 
and PCR techniques that surviving donor cells were everywhere in 
the liver recipientsY-lO All 25 patients had donor cells in their 
tissues obtained by biopsy or at autopsy 2 to 23 years 
post transplantation; 15 of the patients also were blood chimeras 
according to PCR results. 
AuwnenmtlonofChhnerism 
We have summarized elsewhere the evidence that the same 
phenomena occur with other organs.l,lO If these same events occur 
with all whole organ grafts but with quantitative differences, the 
heavy endowment of the liver with these migratory leukocytes 
would explain the well known relative ease of inducing its accep-
tance (sometimes without drugs), its ability to shield other con-
comitantly transplanted organs (hepatic tolerogenicity), and per-
haps even its resistance to preformed antibodies. lO Other organs 
have similar although less tolerogenic potential. The smaller leuko-
cyte substrate in the kidney, for example, would explain why it is 
harder for the renal allograft recipient to achieve drug-free donor-
specific nonreactivity than for the liver patient. 
Fig. 2. Strategies to bring "underprivileged" organs like the heart and kidney 
to the same level of tolerogenicity advantage as the liver, by infusing bone 
marrow cells or other immunocytes from the whole organ donor. 
At this meeting, strategies long advocated by Monaco and 
Thomas (and before them, Leslie Brent) have been discussed to 
elevate the underprivileged kidney and heart to the same level or 
beyond the advantage enjoyed by the liver by infusion of bone 
marrow. The logic of these strategies (Fig. 2) is reinforced by the 
realization that they are extensions or magnifications of a naturally 
occurring process of cell migration. 
As a corollary, it may be suggested that observations about the 
time necessary to establish a drug-free chimeric state in liver 
recipients are predicted to be more or less applicable to the 
management of kidney, heart or other organ recipients given 
adjuvant bone marrow. It is clear that the instant tolerance achieved 
with mixed chimerism in mouse and other rodent systems is an 
illusion for outbred MHC mismatched large animals including 
humans. In human liver recipients, the chimeric state is dependent 
on immunosuppression for highly variable periods. So far, 22 liver 
recipients taken off therapy as early as two months postoperatively 
and as late as 11 years have had drug-free subsequent survival for as 
long as 14 years. We now suspect that the majority of liver recipients 
with a benign course exceeding five years can be weaned from drugs 
- one safety factor being the ability to effectively treat rejection, if 
it does occur, with FK 506. The addition of donor bone marrow to 
the liver transplant operation may shorten the interval of drug 
dependence but it will not eliminate it, even when a high level of 
mixed multilineage chimerism (exceeding 25% of circulating 
white cells) is produced. We already have shown that rejection or 
GVHD can be the price for premature drug weaning. 
Cause and Effect Questions 
about Microchhnerism 
Metabolic Effects 
Aside from their immunologic implications, the seemingly 
sparse peripheralized leukocytes following conventional organ trans-
plantation can profoundly alter total body metabolism as shown in 
three liver transplant recipients who had metabolic storage diseases 
caused by pancellular enzyme deficiencies. In these patients, en-
zymes appeared to have been transported to the host cells by 
chimeric donor cells that were found by cytostaining or PCR in the 
heart, skin, lymph nodes, intestine, bone marrow or blood.9 In two 
patients with the branching enzyme deficiency of Type IV glycogen 
storage disease, the amylopectin characteristic of this disorder was 
absorbed from the heart and other tissues. 
In the patient with Gaucher's disease, chimerism was shown by 
immunostaining and peR in the liver (the hepatocytes of which 
remained donor), and also in the recipient blood, bone marrow, skin, 
small bowel, and lymph nodes. The glucocerebroside deposits 
(Gaucher's cells) in the lymph nodes of this patient diminished 
dramatically over two years.9 
These pancellular storage disorders previously were thought to 
be correctable only with bone marrow transplantation, meaning 
that the liver engraftment is in essence a mini-bone marrow 
transplant. In turn, this implies a co-culture effect of as mall number 
of chimeric donor cells on the contiguous overwhelming numbers 
of recipient cells. Important questions are thereby raised about 
the potential cell to cell effect of other molecules directly 
involved in immunologic processes including those involved in 
tolerance induction. 
The Immunologic Interface 
We have concluded from this recent information that for the last 
30 years we have systematically produced mixed allogeneic chimer-
ism in our whole organ recipients (of kidneys, livers, hearts, lungs, 
or intestines) without knowing it. In the process the coexisting 
immunocyte populations appear to come to view each other in a 
revised light. How this occurs is unknown but it seems clear as 
already discussed that the change is unpredicrable and relatively 
slow under the immunosuppressive regimens in current use, even in 
the most successful cases. The nonreactivity that eventually evolves 
works both ways accounting for the eventual amelioration of whole 
organ rejection (host-versus-graft reaction, HVG) and also for the 
GVHD resistance of the whole organ recipient. Understanding this 
has been the single most importanr factor in our routine ability to 
transplant intestines or multiple viscera. ll The credibility of this 
explanation for the absence of GVHD after transplantation of 
leukocyte rich organs like the liver and intestine is enhanced by 
analogous much earlier obseryations of mixed chimerism in mouse 
bone marrow recipients conditioned by Slavin and Strober with 
total lymphoid irradiationl2 - a procedute that leaves much of the 
host immune system intact -and in the classic mixed bone marrow 
transplant experiments of lids tad and Sachs13 much discussed at this 
meeting. 
In both directions (GVH and HVG), cellular interactions 
resulting in mutual natural immunosuppression (this has been 
called "exhaustive clonal differentiation" by Webb, Morris, and 
Sprentl4) (Fig. 1) are envisioned as occurring on a sliding scale in 
which each further level of histoincompatibility provokes 
countervailing although not equal increases in initial response. If 
the acute storm can be weathered long enough to allow a 
rapprochement, as has been more and more possible under the 
protective umbrella of modern day immunosuppression, the antici-
pated HLA matching effect dwindles. We think this explains the 
poor correlation of tissue matching with outcome in whole organ 
cadaveric transplantation. 
Failure of Mixed Chimerism 
Having thus defined success, it will be prudent in closing to 
define failure. Failure connotes the inability to achieve acceptable 
mixed chimerism and most commonly signifies an imbalance 
despite immunosuppression that favors rejection. However, be-
cause an incipient GVH reaction is a necessary condition for success 
(this is our hypothesis), it is obvious that clinical GVHD is a 
theoretical possibility in every case no matter what the organ (Fig. 
1). For example, we now realize that about 5% of all liver recipients 
have GVHD which in the past usually was attributed to an allergic 
reaction. This kind of GVHD usually can be controlled with 
increased or decreased immunosuppression, but the number of 
reports of a fatal outcome has steadily increased. 
Relation of Cell Migration 
and Chimerism to Tolerance 
Recent reviews have emphasized the inadequacy of thymic 
clonal deletion to explain acquired transplantation tolerance and 
have focused on postthymic mechanisms that include peripheral 
clonal deletion and anergy. However, we note here that all of the 
hypotheses ro explain clonal "silencing", whether or not these are 
called tolerance and are attributed to thymic or postthymic mecha-
nisms, will be enriched by the discovery of the enduring intimacy 
of the chimeric graft and host immunologic systems. 
However, the evidence of vitality and turnover of donor leuko-
cytes in recipient tissues as long as three decades posttransplantation 
is particularly supportive of Coutinho15 who has defined acquired 
tolerance as a high (not anergic) level of sustained immune activity 
in communicating networks more complex than the idiotype 
systems originally postulated by ] erne. 16 Suppressor andlor veto 
cells could be epiphenomena of this kind of activity; it is not too 
much to ask if these are altered dendritic cells. 
Throughout the years, the testing of every genuinely potent 
immunosuppressant has been followed by excited claims of toler-
ance induction when drugs could be stopped after a brief induction 
period. The very simplicity of cell migration and chimerism as a 
common mechanism to explain these accomplishments no matter 
what the site of the drug action cloaked the existence of the chimeric 
phenomenon and delayed its discovery. With the clarifying reason 
of chimerism for the commonality of the end result, it should be 
possible to work backward using drugs with known sites of action 
to ask specific questions and test hypotheses about the true meaning 
of tOlerance. 
Conclusion 
The cell migration concept creates a seamless single world for 
those transplanting bone marrow and those engrafting solid organs. 
Far from involving different mechanisms, these two seemingly 
disparate fields merely reflect different treatment dogmas. The bone 
marrow transplanters eliminate (or minimize) mutual cell engage-
ment by recipient cytoablation and thus commit themselves to 
heavy reliance on HLA matching despite which there is a constant 
threat of GVHD. Solid organ transplanters encourage, or at least 
permit, the mutual cell engagement to occur, thereby liberating 
themselves from the restrictions of HLA matching and an over-
whelming threat ofGVHD. Knowing this, the disciplines reunite. 
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